Latest Breaking News On - In license highly selective - Page 1 : comparemela.com

Announced Agreement With Nimbus Therapeutics in December to Acquire a Potential Best-in-Class TYK2 Inhibitor, and with HUTCHMED in January to In-license Highly Selective, Oral Tyrosine Kinase Inhibitor

United statesHong kongBrendan jenningsSchwierige zeitenChristopher oreillyInternational financial reporting standardsEuropean commissionArrowhead pharmaceuticals incExchange commissionChina national medical products administrationNimbus therapeuticsTakeda pharmaceutical company limitedConstant exchange rateAnnounced agreement with nimbus therapeuticsPotential best in classIn license highly selective